BTI
IBO

Blue Trust Inc’s Impact BioMedical IBO Stock Holding History

Blue Trust Inc’s Portfolio IBO Stock Details IBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
+1
New +$1 ﹤0.01% 2681

Other funds holding IBO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Global Advisers
Vanguard Global Advisers Malvern, Pennsylvania $215B AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Blue Trust Inc's IBO Position: Q2 2026 in Review

Blue Trust Inc opened a new position in Impact BioMedical (IBO) in Q2 2026: 1 share worth $0. The stake represents ﹤0.01% of the portfolio and ranks #2681 among its holdings.

22 funds tracked by Wall St. Rank hold IBO as of Q2 2026.

  • Blue Trust Inc held 1 share of Impact BioMedical worth $0 as of Q2 2026.
  • Impact BioMedical was a new Blue Trust Inc position in Q2 2026.
  • Impact BioMedical made up ﹤0.01% of Blue Trust Inc's portfolio in Q2 2026, its #2681 holding.
  • 22 funds tracked by Wall St. Rank held Impact BioMedical as of Q2 2026.

Based on Blue Trust Inc's 13F filing for Q2 2026, filed 21 Jul 2026.